MONTEREY, Calif. — Progress is being made in the advancement of vision-sparing treatments for uveal melanoma, according to Alison Skalet, MD, PhD.
“Our primary treatments, which are enucleation and irradiation, are highly effective for intraocular tumor control,” Skalet said at the Women in Ophthalmology Summer Symposium, although globe-sparing therapy is associated with vision loss, usually from radiation retinopathy or optic neuropathy.
There are limited treatment options for metastatic disease, she said, but there are new therapeutics on the horizon.
AU-011 (belzupacap